Cartesian Therapeutics, Inc.
RNAC
Kedudukan dalam Saham
#18509
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Harga Saham
$6.11
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$184.86M
Perubahan (1 hari)
-2.55%
Perubahan (1 tahun)
815.63%
Negara
US
Perdagangan Cartesian Therapeutics, Inc. (RNAC)
Kategori
Healthcare
Sejarah pecahan saham untuk Cartesian Therapeutics, Inc. (RNAC)
Saham Cartesian Therapeutics, Inc. (simbol: RNAC) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham RNAC yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham RNAC.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham RNAC yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham RNAC.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
